SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Plandai Biotechnology Inc. (OTC PINK:PLPL) (the "Company") today announced its entry into a non-binding letter of intent to enter into a new business through a proposed product and technology rights licensing agreement with the holder of rights to the unique Puriblood Leukocyte Reduction Blood Filtration System.
Puriblood Medical Co., Ltd. [Taipei Exchange], develops and sells blood cell separation products including its leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. The Puriblood Leukocyte Reduction Blood Filtration System helps ensure the quality of blood used for transfusions, by effectively removing Leukocytes from blood, thereby minimizing acute or delayed adverse transfusion reactions, including infection and death. Currently, approximately thirty countries around the world require leuko-reduction in blood supplies. Puriblood's core blood purification filters reduce up to over 99% of leukocytes, in substantially less time, with minimal blood loss, while retaining a high level of red blood cells (where a higher number of red blood cells retained is desirable). Puriblood's technology is patented in multiple strategic countries, including the United States, and cleared for marketing by the U.S. Food and Drug Administration under Section 510(k) of the Federal Food, Drug, and Cosmetic Act.
Under the terms of the proposed agreement, the current holder of the worldwide rights, exclusive of Taiwan, Jessie Chiang, via entities she controls, will license to Plandai the exclusive rights to the Puriblood technology for North, Central, and South America for a period of 30 years. Upon closing of the proposed transaction, Ms. Chiang will acquire the controlling interest in the Company and will become the Company's Director, President, and Chief Executive Officer. Ms. Chiang will then appoint new members to the board of directors and will move to establish a board of advisors consisting of leading industry, finance, and business experts.
Tad Mailander, the Company's CEO and director commented, "We have been very clear with our shareholders that Plandai has planned to create increased value by merging with another business entity or implementing a positive change in business direction via a new management team. We have been carefully vetting such opportunities, and we are now pleased to present this opportunity to our shareholders. We view this proposed transaction as being in the best interest of our shareholders. Our team is looking forward to completing our due diligence process and ultimately closing on this transaction."
Jessie Chiang commented: "This is an extremely exciting opportunity for the teams of our companies to all work together in synergy to maximize the potential of this frequently essential medical device in the international and domestic market."
The global leukapheresis market is primarily driven by solid growth in voluntary blood donations, rising incidence of hematologic diseases, such as leukemia, and an aging population in many countries. As a result, several industry analysts are forecasting continued strong growth in technologies and products designed for this market. For example, Quince Market Insights, in a report issued late in 2021, estimates the global leukapheresis market will grow at a compound annual growth rate of 43.9% until 2030.
While the parties have agreed to non-binding terms in a letter outlining their intentions, the transaction has not yet been consummated, and there is no assurance that any such transaction will ultimately close. Plandai plans to release additional information concerning the progress of the proposed transaction as soon as possible, upon the completion of its due diligence investigation.
Puriblood is a U.S. registered trademark of Puriblood Medical Co., Ltd. Corporation Taiwan 2f., No. 11, Gongye E. 9th Rd. Hsinchu County 30075 Taiwan R.O.C.
Plandai Biotechnology, Inc., a Nevada corporation, is a publicly quoted shell company seeking to create value for its shareholders by merging with another entity with experienced management and opportunities for growth.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "would," "could," "will" and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash, and other measures of financial performance.
Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties, and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others, such as but are not limited to; economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition, uncontrollable forces of nature, and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements.
Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.
Tad Mailander plandai@prontonmail.com
View source version on accesswire.com: https://www.accesswire.com/702221/Plandai-Biotechnology-In-Non-Binding-Letter-of-Intent-to-Acquire-Rights-to-Puribloods-Leukocyte-Reduction-Blood-Filtration-System-with-Plans-to-Address-the-International-Blood-Filtration-Market
Neither the bear market nor the stock split will have a lasting effect on this company's long-term potential.
Bridgewater’s co–chief investment officer said the U.S. economy could slow down further.
For the second time in three years, Tesla will split its stock, lowering its price and increasing the number of shares outstanding.
The U.S. hasn't yet entered a recession -- which is officially defined as two consecutive quarters of negative GDP growth -- but runaway inflation, stagnant wages, food shortages, rising interest rates, and geopolitical turmoil could all break this fragile economy's back in the near future. If that happens, growth stocks will fall further as value stocks become even more attractive. Altria is the top tobacco company in America.
Your retirement savings are $1 million. You want $100,000 of yearly retirement income, including Social Security. Is that doable without tons of risk?
Los Angeles Capital CIO Hal Reynolds and Truist Chief Market Strategist Keith Lerner join Yahoo Finance Live to examine market sell-offs amid rising inflation and CPI data, defensive portfolio investing, the Fed's interest rate hike cycles, and spiking oil and gas prices.
Since taking the reins as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, Warren Buffett has put on a moneymaking clinic for Wall Street. While there are no shortage of reasons for the Oracle of Omaha's sustained success, his love of dividend stocks could be the most important component. Dividend stocks are almost always profitable and time-tested.
Shares of several major bank stocks took a hit today after new data showed that inflation is still surging and may not have peaked yet. The Dow Jones Industrial Average had lost more than 650 points as of this writing while the Nasdaq Composite was down close to 3%. Shares of Citigroup (NYSE: C) traded 4.3% lower as of 2:25 p.m. ET today, shares of JPMorgan Chase (NYSE: JPM) were 4.2% lower, and shares of Goldman Sachs (NYSE: GS) were down 4.8%.
In this article, we discuss 10 beaten-down Asian stocks to buy today. If you want to see more stocks in this selection, click 5 Beaten-Down Asian Stocks to Buy Today. While the US dollar remains strong, Asian markets on June 10 stumbled on the back of higher rates guidance from the European Central Bank and […]
“Ball of confusion, that's what the world is today,” sang the Temptations on their 1970 classic, a sentiment which can readily apply to the stock market’s present state. It’s hard to get a grip on the market’s choppy action in 2022 and investors could use a clear signal to follow when considering a new investment. One way to get a head start is by tracking the moves of the insiders. These are the corporate officers with in-depth knowledge of the companies they helm. To keep the playing field lev
ChargePoint, Autoliv, and QuantumScape look like excellent long-term bets, despite the near-term headwinds they face.
Markets are volatile. Use these dividend stocks for peace of mind.
Friday’s consumer-price index report for May — which showed the annual headline U.S. inflation rate climbing to 8.6% in May, with few signs of having peaked — is boosting the chances of a jumbo-sized rate increase by monetary-policy makers as soon as next week, and eliciting dire warnings that central bankers have completely lost control of prices. Fed funds futures traders now see a 21% chance of a 75-basis-point hike in June, up from just 3.6% on Thursday, according to the CME FedWatch Tool. Beneath the issue of where the Fed goes from here is a much more fundamental and serious problem: Some observers fear the U.S. central bank has already effectively lost control of inflation.
AMD painted a bright picture of its growing market opportunity, especially in data centers, at an analyst day presentation.
Yahoo Finance Live's Seana Smith reports breaking news that EV manufacturer Tesla has filed for a 3-for-1 stock split.
Inflation remains white-hot. These stocks can help stop the pain.
U.S. stocks sank Friday as investors digested two downbeat prints on the U.S. economy.
Inflation has yet to peak and has only gotten worse since 2021, Tim Magnusson, chief investment officer of Garda Capital Partners, tells MarketWatch.
Inflation and rising mortgage costs are putting a dent in housing prices, which in turn is reducing lumber demand.
(Bloomberg) -- Traders are now fully pricing three half-point Federal Reserve rate hikes in coming months, while the 30-year Treasury yield fell below its five-year counterpart for the first time in a month. Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenEating Two Portions of Fish Per Week Linked to Deadly Skin CancerFive Key Moments From the Jan. 6 Capitol Riot HearingYields Spike to 2008 High, S